Mohammadi Barzelighi Hajar, Daraei Bahram, Dastan Farzaneh
Biosun Pharmed Factory, Barkat Pharmaceutical Group, Tehran, Iran.
Department of Toxicology and Pharmacology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Iran J Pharm Res. 2020 Summer;19(3):258-281. doi: 10.22037/ijpr.2020.113821.14506.
The emergence of a novel Coronavirus disease (COVID-19) inducing acute respiratory distress syndrome (ARDS) was identified in Hubei province of China in December 2019 and rapidly spread worldwide as pandemic and became a public health concern. COVID-19 disease is caused by a new virus known as SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), which has recently offered many challenges and efforts to identify effective drugs for its prevention and treatment. Currently, there is no proven effective approach and medication against this virus. Quickly expanding clinical trials and studies on Coronavirus disease 2019 increase our knowledge regarding SARS-CoV-2 virus and introduce several potential drugs targeting virus moiety or host cell elements. Overall, 3 stages were suggested for SARS-CoV-2 infection according to the disease severity, clinical manifestations, and treatment outcomes, including mild, moderate, and severe. This review aimed to classify and summarize several medications and potential therapies according to the disease 3 stages; however, it is worth noting that no medication and therapy has been effective so far.
2019年12月,在中国湖北省发现了一种新型冠状病毒病(COVID-19),它可引发急性呼吸窘迫综合征(ARDS),并迅速在全球范围内大流行,成为一个公共卫生问题。COVID-19疾病由一种名为严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的新型病毒引起,最近在确定其预防和治疗的有效药物方面带来了诸多挑战并付出了很多努力。目前,尚无针对这种病毒的经证实有效的方法和药物。针对2019冠状病毒病的快速扩展的临床试验和研究增加了我们对SARS-CoV-2病毒的了解,并引入了几种针对病毒部分或宿主细胞成分的潜在药物。总体而言,根据疾病严重程度、临床表现和治疗结果,SARS-CoV-2感染分为3个阶段,包括轻症、中症和重症。本综述旨在根据疾病的3个阶段对几种药物和潜在疗法进行分类和总结;然而,值得注意的是,迄今为止尚无药物和疗法有效。